{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/dsip",
  "canonicalUrl": "https://thepeptidefield.com/peptides/dsip",
  "record": {
    "slug": "dsip",
    "name": "DSIP",
    "aliases": [
      "Emideltide",
      "Delta sleep-inducing peptide"
    ],
    "className": "Sleep-related peptide",
    "family": "Sleep-related peptides",
    "sequenceLabel": "9 amino acids · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)",
    "tier": "Insufficient",
    "evidenceContext": "Investigational human outcomes",
    "statusLine": "No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list",
    "productContext": "DSIP is also called emideltide. FDA separates emideltide free base from emideltide acetate, a salt form. These forms are not automatically the same as each other or as a product sold online. A product name does not prove its identity, contents, quality, or match to study material.",
    "approvedProducts": [],
    "productRecords": [],
    "indications": [
      "Small human studies of sleep",
      "Small human studies of withdrawal symptoms"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Limited",
        "note": "Small older human studies gave DSIP mainly through a vein and reported mixed sleep results. The studies do not establish a treatment benefit."
      },
      "humanPharmacology": {
        "level": "Unclear",
        "note": "Some studies measured short-term sleep or hormone changes after use through a vein. They do not define how DSIP acts in every person or product."
      },
      "safetyKnowledge": {
        "level": "Unclear",
        "note": "FDA found no adequate long-term safety data and no human safety evidence for the proposed under-the-skin route. Product quality and immune-reaction risks remain uncertain."
      },
      "productCertainty": {
        "level": "Unclear",
        "note": "FDA separates free base and acetate. Online products may not match either form or the material used in human studies."
      }
    },
    "oneLine": "DSIP is a nine-amino-acid peptide. Studies do not prove it works. FDA has not approved DSIP.",
    "reviewedAt": "August 30, 2026",
    "reviewedAtISO": "2026-08-30",
    "reviewHistory": [
      {
        "date": "2026-08-30",
        "note": "Initial brief reviewed FDA identity and compounding records, the July 2026 advisory-committee record, and small human studies of sleep, hormone changes, narcolepsy, and withdrawal symptoms."
      }
    ],
    "whatItIs": "DSIP, also called emideltide or delta sleep-inducing peptide, is a peptide with nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). Free base and acetate are different chemical forms. The 503A list is a U.S. list of bulk substances that may be used in some pharmacy compounding. A listed substance is not automatically an approved drug.",
    "whatWeKnow": "Small sleep studies from 1981 through 1992 tested DSIP, mostly through a vein. Some reported short sleep changes. Other controlled studies found little or no useful sleep benefit. One study measured a short-term change in a blood hormone, not better sleep. A few small studies also looked at narcolepsy or withdrawal symptoms.",
    "whatWeDoNotKnow": "These studies do not prove that DSIP improves sleep, treats insomnia, or treats opioid or alcohol withdrawal. The studies were small and used different designs. They do not show long-term benefit or safety. FDA's 2026 review found no adequate evidence for the proposed under-the-skin route and no long-term effectiveness data. It also found no adequate safety or toxicity record for the proposed use.",
    "antiDoping": null,
    "safetyBoundary": "FDA identified important limits in the human safety and product-quality record. Free base, acetate, and online products may differ. This guide gives no dosing, administration, sourcing, product-selection, or treatment instructions.",
    "relatedSlugs": [
      "semax",
      "epitalon",
      "cerebrolysin"
    ],
    "claims": [
      {
        "claim": "“DSIP and emideltide refer to the same nine-amino-acid peptide.”",
        "verdict": "Supported with scope",
        "explanation": "Yes. FDA's substance and briefing records use emideltide for DSIP and identify a nine-amino-acid sequence. This name match does not make free base, acetate, or online products equivalent.",
        "category": "Mechanism and biomarkers",
        "evidenceBasis": "Regulatory or product record",
        "scope": "FDA substance identity records for DSIP and emideltide; this does not establish the identity or quality of an online product.",
        "sourceUrls": [
          "https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73",
          "https://www.fda.gov/media/193344/download"
        ]
      },
      {
        "claim": "“DSIP is proven to improve sleep or treat insomnia.”",
        "verdict": "Not established",
        "explanation": "Small older human studies had mixed results. Some used controls, while others had important design limits. Together, they do not prove that DSIP improves sleep or treats insomnia.",
        "category": "Clinical outcomes",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Small human sleep studies using different designs, products, routes, and follow-up periods; the results do not establish a general treatment benefit.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/6895513/",
          "https://pubmed.ncbi.nlm.nih.gov/7028502/",
          "https://pubmed.ncbi.nlm.nih.gov/6112579/",
          "https://pubmed.ncbi.nlm.nih.gov/3622582/",
          "https://pubmed.ncbi.nlm.nih.gov/3583493/",
          "https://pubmed.ncbi.nlm.nih.gov/1299794/",
          "https://www.fda.gov/media/193344/download"
        ]
      },
      {
        "claim": "“DSIP treats opioid or alcohol withdrawal.”",
        "verdict": "Not established",
        "explanation": "Small older studies examined withdrawal symptoms, but they did not establish that DSIP treats opioid or alcohol withdrawal. The findings do not support a general treatment claim.",
        "category": "Clinical outcomes",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "The small human withdrawal studies reviewed; this does not establish a treatment benefit for withdrawal or any other condition.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/6548969/",
          "https://pubmed.ncbi.nlm.nih.gov/9617990/"
        ]
      },
      {
        "claim": "“DSIP is FDA-approved in the United States.”",
        "verdict": "Misleading",
        "explanation": "FDA's briefing did not identify an FDA-approved U.S. drug containing emideltide. The current U.S. 503A list also does not list DSIP or emideltide. A substance record or a foreign or online product is not U.S. drug approval.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "United States approval and 503A status as reviewed August 30, 2026.",
        "sourceUrls": [
          "https://www.fda.gov/media/193344/download",
          "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23"
        ]
      },
      {
        "claim": "“The 2026 advisory vote added DSIP to the 503A list or approved it.”",
        "verdict": "Misleading",
        "explanation": "The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.",
        "category": "Approval and status",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval.",
        "sourceUrls": [
          "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
          "https://www.fda.gov/media/193344/download",
          "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23"
        ]
      },
      {
        "claim": "“Emideltide free base, emideltide acetate, and online DSIP products are interchangeable.”",
        "verdict": "Misleading",
        "explanation": "FDA separates emideltide free base and emideltide acetate. An online product may have a different form, contents, or quality. The names alone do not show that these products are interchangeable.",
        "category": "Product equivalence",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Chemical-form and product-identity comparisons; this is not a use or administration recommendation.",
        "sourceUrls": [
          "https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73",
          "https://www.fda.gov/media/193344/download"
        ]
      }
    ],
    "sources": [
      {
        "label": "FDA Global Substance Registration System record for emideltide (DSIP)",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "FDA evaluation of emideltide (DSIP) and related bulk drug substances",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/media/193344/download",
        "kind": "FDA review",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "21 CFR 216.23 bulk drug substances list",
        "publisher": "Electronic Code of Federal Regulations",
        "url": "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23",
        "kind": "Regulatory",
        "year": 2026,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "DSIP amino-acid sequence, synthesis, and activity",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/568769/",
        "kind": "Reference",
        "year": 1978,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Acute and delayed effects of DSIP on human sleep behavior",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/6895513/",
        "kind": "Randomized trial",
        "year": 1981,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Synthetic DSIP and disturbed human sleep",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/7028502/",
        "kind": "Human clinical study",
        "year": 1981,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Synthetic DSIP and sleep in people with insomnia",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/6112579/",
        "kind": "Human clinical study",
        "year": 1981,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "DSIP and 24-hour sleep-wake behavior in severe chronic insomnia",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/3622582/",
        "kind": "Human clinical study",
        "year": 1987,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "DSIP efficacy study in chronic insomnia",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/3583493/",
        "kind": "Randomized trial",
        "year": 1987,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Double-blind DSIP study in chronic insomnia",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/1299794/",
        "kind": "Randomized trial",
        "year": 1992,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "DSIP and narcolepsy",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/6548968/",
        "kind": "Human pilot",
        "year": 1984,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "DSIP in withdrawal syndromes from alcohol and opiates",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/6548969/",
        "kind": "Human clinical study",
        "year": 1984,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Opioid detoxification with DSIP: open clinical trial",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/9617990/",
        "kind": "Human pilot",
        "year": 1998,
        "accessedAt": "2026-08-30"
      },
      {
        "label": "Intravenous DSIP and a blood hormone change in people",
        "publisher": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/2554357/",
        "kind": "Human pharmacology",
        "year": 1989,
        "accessedAt": "2026-08-30"
      }
    ],
    "antiDopingReview": {
      "status": "Not assessed",
      "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.",
      "sourceUrl": null,
      "reviewedAtISO": "2026-08-30"
    }
  }
}